NCT06875310 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT06875310
Title	A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Acronym	KRYSTAL-4
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	No
Sponsors	Mirati Therapeutics Inc.
Indications	lung non-squamous non-small cell carcinoma
Therapies	Cisplatin + Pembrolizumab + Pemetrexed Disodium Adagrasib + Carboplatin + Pembrolizumab + Pemetrexed Disodium Adagrasib + Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| ROU \| POL \| NLD \| ITA \| ISR \| IRL \| HUN \| HRV \| GRC \| GBR \| FRA \| ESP \| DEU \| CHE \| CAN \| BRA \| BGR \| BEL \| AUT \| AUS \| ARG

No variant requirements are available.